A detailed history of Bank Of America Corp transactions in Erasca, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 4,220,671 shares of ERAS stock, worth $11.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,220,671
Previous 1,721,710 145.14%
Holding current value
$11.5 Million
Previous $4.06 Million 183.58%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.17 - $3.28 $5.42 Million - $8.2 Million
2,498,961 Added 145.14%
4,220,671 $11.5 Million
Q2 2024

Aug 14, 2024

SELL
$1.79 - $2.63 $855,406 - $1.26 Million
-477,881 Reduced 21.73%
1,721,710 $4.06 Million
Q1 2024

May 15, 2024

BUY
$1.67 - $2.55 $2.46 Million - $3.76 Million
1,472,840 Added 202.66%
2,199,591 $4.53 Million
Q4 2023

Feb 14, 2024

BUY
$1.67 - $2.49 $178,053 - $265,481
106,619 Added 17.19%
726,751 $1.55 Million
Q2 2023

Aug 14, 2023

SELL
$2.57 - $3.3 $6.06 Million - $7.78 Million
-2,356,385 Reduced 79.17%
620,132 $1.71 Million
Q1 2023

May 12, 2023

BUY
$2.74 - $4.44 $806,055 - $1.31 Million
294,181 Added 10.97%
2,976,517 $8.96 Million
Q4 2022

Feb 10, 2023

BUY
$3.89 - $8.57 $10.1 Million - $22.3 Million
2,596,609 Added 3028.93%
2,682,336 $11.6 Million
Q3 2022

Nov 14, 2022

BUY
$5.82 - $10.68 $408,726 - $750,035
70,228 Added 453.11%
85,727 $669,000
Q2 2022

Aug 12, 2022

BUY
$4.58 - $8.72 $7,442 - $14,170
1,625 Added 11.71%
15,499 $86,000
Q1 2022

May 16, 2022

BUY
$8.6 - $15.48 $36,980 - $66,564
4,300 Added 44.91%
13,874 $120,000
Q4 2021

Feb 08, 2022

SELL
$12.51 - $22.75 $26,909 - $48,935
-2,151 Reduced 18.35%
9,574 $149,000
Q3 2021

Nov 15, 2021

BUY
$17.43 - $24.34 $204,366 - $285,386
11,725 New
11,725 $249,000

Others Institutions Holding ERAS

About Erasca, Inc.


  • Ticker ERAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 122,147,000
  • Market Cap $333M
  • Description
  • Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...
More about ERAS
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.